Page last updated: 2024-08-21

fluorobenzenes and Abdominal Obesity

fluorobenzenes has been researched along with Abdominal Obesity in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barrett, PH; Chan, DC; Meikle, PJ; Ng, TW; Ooi, EM; Watts, GF1
Hu, M; Lee, MH; Mak, VW; Tomlinson, B1

Trials

1 trial(s) available for fluorobenzenes and Abdominal Obesity

ArticleYear
Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:6

    Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Ceramides; Fluorobenzenes; Humans; Kinetics; Lipid Metabolism; Lipoproteins, VLDL; Male; Metabolic Syndrome; Metabolism; Middle Aged; Obesity, Abdominal; Pyrimidines; Rosuvastatin Calcium; Sphingomyelins; Sulfonamides

2015

Other Studies

1 other study(ies) available for fluorobenzenes and Abdominal Obesity

ArticleYear
Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).
    The American journal of cardiology, 2010, Dec-01, Volume: 106, Issue:11

    Topics: Aged; C-Reactive Protein; China; Cholesterol, HDL; Coronary Disease; DNA; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Nephelometry and Turbidimetry; Obesity, Abdominal; Polymorphism, Genetic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides

2010